Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved NeuroBloc er større end risiciene ved behandling af cervikal dystoni (torticollis).
The Committee for Medicinal Products for Human Use (CHMP) decided that NeuroBloc’ s benefits are greater than its risks for the treatment of cervical dystonia (torticollis).